Demant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022
Oticon Medical, the surgical division of hearing aid group Demant, has located a performance issue in a number of non-implanted Neuro Zti cochlear implants, and the company sees no other option than to immediately withdraw the product from the market.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
Bad things often happen in threes, and they just keep coming for hearing aid manufacturer Demant. First, the company was hit by a cyber attack which effectively shut down the company for weeks, then the pandemic hit, and now Oticon Medical, the sugical division at Demant, is experiencing headwind.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Apple investigating Airpods as hearing health solution
For subscribers
Demant increases Veterans Affairs market share slightly
For subscribers
